Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From The Year-End Conference Calls....

Executive Summary

Lilly GMP issues: Lilly will be "inspection-ready" at the Cymbalta dry products facility in the first quarter, with the Zyprexa IM parental facility FDA-ready "some time later," Exec Director-Investor Relations Simon Harford tells Jan. 23 conference call. "Whether they will have a date specified up-front or whether they will just arrive, which they have the right to do, is still yet to be determined." Although Lilly acknowledged that "significant dialogue" with FDA remains, "as time goes on, I think we feel a bit more positive about our situation on the manufacturing side," CFO Charles Golden says. "We've had no discussions whatsoever about a consent decree with them"...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS041155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel